Webinar Overview
As a drug discovery professional, you are likely to feel constant pressure to innovate, reaching for ever-evolving standards in safety, efficiency, and early candidate confidence. Have you considered how human protein libraries are enabling innovation?
Join us to learn how a protein library is built, and how it must evolve to serve the goals and ambitions of the drug discovery community. We have also invited an expert from GlaxoSmithKline (GSK) to discuss how they screened their new COVID therapy Xevudy® for specificity against prenatal proteins.
- Discover how screening library development impacts clinical trial demographics, patient care, and the 3Rs
- Understand how specificity data impacts lead candidate selection, safety assessment and regulatory submission
- Learn about identifying and mitigating the risk of off-target clinical toxicity
Webinar Presenters
Diogo Rodrigues, MSc Biochemistry
Senior Client Manager, Discovery
Charles River
Curtis Maier, PhD
Head, Immunological Toxicology
GlaxoSmithKline
Additional Information
- De-Risking Therapies and Vaccines for use During Pregnancy
- Identifying Primary Receptors and Off-Targets
- Off-Target Screening of Biotherapeutics
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.